Last reviewed · How we verify
NCT07188116
Correlation Between COVID-19 and Radiation Pneumonitis in Breast Cancer
trial testing COVID-19 in Breast Cancer in 200 participants. Not yet recruiting.
31 December 2025
Quick facts
| Lead sponsor | Zhejiang Hospital |
|---|---|
| Status | Not yet recruiting |
| Study type | OBSERVATIONAL |
| Enrollment | 200 |
| Start date | 15 September 2025 |
| Primary completion | 31 December 2025 |
| Estimated completion | 31 December 2025 |
| Sites | 1 location across China |
Drugs / interventions tested
- COVID-19 — full drug profile →
Conditions studied
- Breast Cancer — all drugs for Breast Cancer →
- Radiation Pneumonia — all drugs for Radiation Pneumonia →
- COVID-19 — all drugs for COVID-19 →
Sponsor
Zhejiang Hospital
Who can join
Adults 18 to 80, female only, with Breast Cancer or Radiation Pneumonia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study was designed as a single-center retrospective analysis aimed at investigating whether COVID-19 infection increases the risk or burden of radiation-induced pneumonitis in breast cancer patients.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07188116
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of COVID-19
Trials testing the same drug.
- NCT05429047 — Priming of the NEonatal Immune System by Transfer of Maternal Immunity · unknown
- NCT05481216 — HIV-1 & Coronavirus-Coinfection in Europe: Morbidity & Risk Factors of COVID-19 in People Living With HIV · completed
- NCT05222750 — Epidemiology of Thrombotic Thrombocytopenia Syndrome in Integrated Health-care Database in England · completed
- NCT05252442 — Association of the Risk for Thrombotic Thrombocytopenia Syndrome and Exposure To COVID-19 Vaccines · completed
- NCT05225194 — Long-term Impact of COVID-19 Among COVID-19 Patients With Acute Respiratory Distress Syndrome in Brazil · unknown
Other recruiting trials for Breast Cancer
Currently open trials in the same condition.
- NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
- NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
- NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
- NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
- NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting
Other Zhejiang Hospital trials
Trials by the same sponsor.
- NCT07059871 — A Study of Silkworm Pupa Powder Intervention in the Nutritional Status of Patients With Alzheimer's Disease. · NA · recruiting
- NCT07429630 — Predictors of Physical Improvement in Frail Hospitalized Elders After Nutrition and Exercise · NA · completed
- NCT07510035 — Prevalence and Influencing Factors of Frailty in Elderly Patients With Heart Failure · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07188116 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Zhejiang Hospital
- Last refreshed: 23 September 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07188116.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing